Nicholas Crossfield Overview
- Investor Type
-
Angel
- Investments
-
1
- Exits
-
2
Nicholas Crossfield General Information
Description
Mr. Nicholas Crossfield is an Angel Investor. Mr. Crossfield serves as Chief Executive Officer at AC Biogas. Mr. Crossfield served as Managing Director and Chief Executive Officer at Invensys Rail Group and Managing Director, Siemens Rail Automation.
Business Details
Primary Investor Type
Nicholas Crossfield Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | 19-Sep-2014 | Pharmaceuticals | Generating Revenue/Not Profitable |
Nicholas Crossfield Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Adaptimmune Therapeutics | 30-Aug-2019 | Secondary Transaction - Open Market | |
| Adaptimmune Therapeutics | 06-May-2015 |
Nicholas Crossfield Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Nicholas Crossfield FAQs
-
Who is Nicholas Crossfield?
Nicholas Crossfield is an angel Investor who has made 1 investment.
-
What kind of investor is Nicholas Crossfield?
Nicholas Crossfield is an angel investor.
-
What does Nicholas Crossfield do?
As an angel investor, Nicholas Crossfield invests personal money into promising companies, typically in exchange for equity.
-
What has Nicholas Crossfield invested in?
Nicholas Crossfield has invested in Adaptimmune Therapeutics within the Pharmaceuticals industry.
-
What has Nicholas Crossfield invested in recently?
Nicholas Crossfield's latest investment was on 19-Sep-2014 in Adaptimmune Therapeutics, a company within the Pharmaceuticals industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
